ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO164

Clinical Features and Outcomes of Calciphylaxis in Chinese Patients With CKD

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical


  • Jiao, Yongyi, Zhong Da Hospital affiliated to Southeast University, Nanjing, Jiangsu, China
  • Zhang, Xiaoliang, Zhong Da Hospital affiliated to Southeast University, Nanjing, Jiangsu, China

Calciphylaxis is a rare disease, predominantly in chronic kidney disease (CKD), characterized by high morbidity and mortality. Data from the Chinese population have been an invaluable resource for a better understanding of natural history, optimal treatments, and outcomes of calciphylaxis.


A retrospective study was conducted in 51 Chinese patients diagnosed with calciphylaxis at Zhong Da Hospital affiliated to Southeast University from December 2015 to September 2020. Descriptive statistical analysis was used in summarizing patients' characteristics, treatments and disease outcomes. Kaplan-Meier method was used to calculate survival. Univariate COX regression models were used to determine survival predictors of patients with calciphylaxis.


Between 2015 and 2020, 51 cases of calciphylaxis were registered in The China Calciphylaxis Registry (, which were developed by Zhong Da Hospital. The mean age of the cohort was 52.02±14.09 years, and 37.3% of them were female. 43 patients (84.3%) were on hemodialysis, with a median dialysis vintage of 88 months. 18 patients (35.3%) had a resolution of calciphylaxis and 20 patients (39.2%) died. Patients in later stages had worse survival than those in earlier stages. Time of skin lesions and calciphylaxis-related infection were risk factors in both early mortality and overall mortality. Additionally, dialysis vintage and infections were significant risk factors in calciphylaxis-specific mortality. Among therapeutic strategies, only the use of STS ≥3 courses was significantly associated with decreased hazard of death.


For Chinese patients with calciphylaxis, time of skin lesions and infection secondary to wounds are risk factors for the prognosis of patients with calciphylaxis. Additionally, patients in earlier stages have a better survival rate and early continuous use of STS is highly suggested.

Overall mortality survival for stratified into calciphylaxis patients in earlier and later stages